CRISPR Therapeutics AG (CRSP)
55.47
-0.75
(-1.33%)
USD |
NASDAQ |
May 20, 16:00
55.42
-0.05
(-0.09%)
After-Hours: 20:00
CRISPR Therapeutics Total Liabilities (Quarterly): 355.08M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 355.08M |
December 31, 2023 | 346.77M |
September 30, 2023 | 359.04M |
June 30, 2023 | 380.99M |
March 31, 2023 | 389.47M |
December 31, 2022 | 367.58M |
September 30, 2022 | 399.40M |
June 30, 2022 | 372.53M |
March 31, 2022 | 361.26M |
December 31, 2021 | 352.42M |
September 30, 2021 | 308.80M |
June 30, 2021 | 295.72M |
March 31, 2021 | 152.41M |
December 31, 2020 | 163.73M |
September 30, 2020 | 141.72M |
June 30, 2020 | 135.86M |
March 31, 2020 | 121.20M |
Date | Value |
---|---|
December 31, 2019 | 127.33M |
September 30, 2019 | 128.71M |
June 30, 2019 | 126.56M |
March 31, 2019 | 118.06M |
December 31, 2018 | 96.82M |
September 30, 2018 | 101.59M |
June 30, 2018 | 87.98M |
March 31, 2018 | 84.12M |
December 31, 2017 | 83.51M |
September 30, 2017 | 103.36M |
June 30, 2017 | 107.17M |
March 31, 2017 | 107.17M |
December 31, 2016 | 112.12M |
September 30, 2016 | 341.18M |
June 30, 2016 | 157.72M |
December 31, 2015 | 188.55M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
121.20M
Minimum
Mar 2020
399.40M
Maximum
Sep 2022
269.33M
Average
327.78M
Median
Total Liabilities (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 5.371B |
Novartis AG | 54.58B |
Intellia Therapeutics Inc | 223.45M |
Regeneron Pharmaceuticals Inc | 7.378B |
Viking Therapeutics Inc | 33.63M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 2.439B |
Shareholders Equity (Quarterly) | 2.084B |